2024
Commentary on Gregory et al.: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation
Springer S. Commentary on Gregory et al.: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation. Addiction 2024 PMID: 39494653, DOI: 10.1111/add.16701.Peer-Reviewed Original ResearchOpioid withdrawalBuprenorphine initiation
2023
Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial
Seval N, Nunez J, Roth P, Schade M, Strong M, Frank C, Litwin A, Levin F, Brady K, Nunes E, Springer S. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal Of Addiction Medicine 2023, 17: e232-e239. PMID: 37579095, PMCID: PMC10368784, DOI: 10.1097/adm.0000000000001136.Peer-Reviewed Original ResearchConceptsOpioid use disorderFull agonist opioidsAgonist opioidsHospital dischargeCase seriesSurgical interventionUse disordersCurrent opioid use disorderInfectious disease physiciansLow-dose strategyMulticenter clinical trialPotential surgical interventionLife-threatening infectionsCOMMIT trialComplex hospitalizationsDepot buprenorphineOpioid relapseUnderused medicationsOpioid withdrawalSublingual buprenorphineBuprenorphine dosesDisease physiciansConcurrent painClinical trialsConcurrent infection
2018
A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine
Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, Springer SA. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 86: 86-93. PMID: 29415856, PMCID: PMC5808584, DOI: 10.1016/j.jsat.2018.01.003.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyXR-NTXExtended-release naltrexonePsychological supportOpioid use disorderHIV prevention effortsFocus groupsPerceptions of recoveryAgonist therapyOpioid withdrawalYoung PWIDOpioid antagonistPatient preferencesNew pharmacotherapiesPsychoactive medicationsInjection careerUse disordersFocus group transcriptsPWIDPrevention effortsNaltrexoneGroup transcriptsIndividual barriersTreatmentWithdrawal